This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weber, W. A. Search for Related Content PubMed PubMed Citation Articles by Weber, W. A. Social Bookmarking                            What's this?

Positron Emission Tomography As an Imaging Biomarker

From the Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, University of California, Los Angeles (UCLA), Los Angeles, CA

Address reprint requests to Wolfgang A. Weber, MD, Department of Molecular Medicine and Pharmacology, David Geffen School of Medicine, UCLA, 10833 Le Conte Ave, Los Angeles, CA 90095; e-mail: wweber{at}mednet.ucla.edu

Positron emission tomography (PET) allows noninvasive, quantitative studies of various biologic processes in the tumor tissue. By using PET, investigators can study the pharmacokinetics of anticancer drugs, identify various therapeutic targets and monitor the inhibition of these targets during therapy. Furthermore, PET provides various markers to assess tumor response early in the course of therapy. A significant number of studies have now shown that changes in tumor glucose utilization during the first weeks of chemotherapy are significantly correlated with patient outcome. These data suggest that PET may be used as a sensitive test to assess the activity of new cytotoxic agents in phase II studies. Furthermore, early identification of nonresponding tumors provides the opportunity to adjust treatment regimens according to the individual chemosensitivity of the tumor tissue. However, further prospective and randomized validation of PET is still required before PET controlled chemotherapy can be used in clinical practice.

Supported by UCLA Center for In-Vivo Imaging in Cancer Biology (National Institutes of Health [NIH] Grant No. P50 CA86306), UCLA Institute of Molecular Medicine (Grant No. DE-FC03-87E60615), and UCLA Lung SPORE (NIH Grant No. P50 CA9038).

Author's disclosures of potential conflicts of interest are found at the end of this article.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R. L. Wahl, H. Jacene, Y. Kasamon, and M. A. Lodge From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors J. Nucl. Med., May 1, 2009; 50(Suppl_1): 122S - 150S. [Abstract] [Full Text] [PDF]

				N. Avril, S. Sassen, and R. Roylance Response to Therapy in Breast Cancer J. Nucl. Med., May 1, 2009; 50(Suppl_1): 55S - 63S. [Abstract] [Full Text] [PDF]

				B. J. Krause, K. Herrmann, H. Wieder, and C. M. zum Buschenfelde 18F-FDG PET and 18F-FDG PET/CT for Assessing Response to Therapy in Esophageal Cancer J. Nucl. Med., May 1, 2009; 50(Suppl_1): 89S - 96S. [Abstract] [Full Text] [PDF]

				M. R. Benz, J. Czernin, M. S. Allen-Auerbach, W. D. Tap, S. M. Dry, D. Elashoff, K. Chow, V. Evilevitch, J. J. Eckardt, M. E. Phelps, et al. FDG-PET/CT Imaging Predicts Histopathologic Treatment Responses after the Initial Cycle of Neoadjuvant Chemotherapy in High-Grade Soft-Tissue Sarcomas Clin. Cancer Res., April 15, 2009; 15(8): 2856 - 2863. [Abstract] [Full Text] [PDF]

				S. Kim, L. Loevner, H. Quon, E. Sherman, G. Weinstein, A. Kilger, and H. Poptani Diffusion-Weighted Magnetic Resonance Imaging for Predicting and Detecting Early Response to Chemoradiation Therapy of Squamous Cell Carcinomas of the Head and Neck Clin. Cancer Res., February 1, 2009; 15(3): 986 - 994. [Abstract] [Full Text] [PDF]

				J. O. Prior, M. Montemurro, M.-V. Orcurto, O. Michielin, F. Luthi, J. Benhattar, L. Guillou, V. Elsig, R. Stupp, A. B. Delaloye, et al. Early Prediction of Response to Sunitinib After Imatinib Failure by 18F-Fluorodeoxyglucose Positron Emission Tomography in Patients With Gastrointestinal Stromal Tumor J. Clin. Oncol., January 20, 2009; 27(3): 439 - 445. [Abstract] [Full Text] [PDF]

				P S MURPHY, T J McCARTHY, and A S K DZIK-JURASZ The role of clinical imaging in oncological drug development Br. J. Radiol., September 1, 2008; 81(969): 685 - 692. [Abstract] [Full Text] [PDF]

				R. H. Brown, C. G. Irvin, G. B. Allen III, S. D. Shapiro, W. J. Martin, M. R. J. Kolb, D. M. Hyde, G. F. Nieman, D. D. Cody, M. Ishii, et al. An Official ATS Conference Proceedings: Advances in Small-Animal Imaging Application to Lung Pathophysiology Proceedings of the ATS, July 15, 2008; 5(5): 591 - 600. [Full Text] [PDF]

				P. T. Winnard Jr., A. P. Pathak, S. Dhara, S. Y. Cho, V. Raman, and M. G. Pomper Molecular Imaging of Metastatic Potential J. Nucl. Med., June 1, 2008; 49(Suppl_2): 96S - 112S. [Abstract] [Full Text] [PDF]

				A. J. Beer, M. Niemeyer, J. Carlsen, M. Sarbia, J. Nahrig, P. Watzlowik, H.-J. Wester, N. Harbeck, and M. Schwaiger Patterns of {alpha}v{beta}3 Expression in Primary and Metastatic Human Breast Cancer as Shown by 18F-Galacto-RGD PET J. Nucl. Med., February 1, 2008; 49(2): 255 - 259. [Abstract] [Full Text] [PDF]

				A. J. Beer, S. Lorenzen, S. Metz, K. Herrmann, P. Watzlowik, H.-J. Wester, C. Peschel, F. Lordick, and M. Schwaiger Comparison of Integrin {alpha}v 3 Expression and Glucose Metabolism in Primary and Metastatic Lesions in Cancer Patients: A PET Study Using 18F-Galacto-RGD and 18F-FDG J. Nucl. Med., January 1, 2008; 49(1): 22 - 29. [Abstract] [Full Text] [PDF]

				A. J. Beer, A.-L. Grosu, J. Carlsen, A. Kolk, M. Sarbia, I. Stangier, P. Watzlowik, H.-J. Wester, R. Haubner, and M. Schwaiger [18F]Galacto-RGD Positron Emission Tomography for Imaging of {alpha}v{beta}3 Expression on the Neovasculature in Patients with Squamous Cell Carcinoma of the Head and Neck Clin. Cancer Res., November 15, 2007; 13(22): 6610 - 6616. [Abstract] [Full Text] [PDF]

				A. H. Khandani, B. F. Calvo, B. H. O'Neil, J. Jorgenson, and M. A. Mauro A Pilot Study of Early 18F-FDG PET to Evaluate the Effectiveness of Radiofrequency Ablation of Liver Metastases Am. J. Roentgenol., November 1, 2007; 189(5): 1199 - 1202. [Abstract] [Full Text] [PDF]

				R. A. Herbertson, S. T. Lee, N. Tebbutt, and A. M. Scott The expanding role of PET technology in the management of patients with colorectal cancer Ann. Onc., November 1, 2007; 18(11): 1774 - 1781. [Abstract] [Full Text] [PDF]

				F. Al-Ejeh, J. M. Darby, K. Pensa, K. R. Diener, J. D. Hayball, and M. P. Brown In vivo Targeting of Dead Tumor Cells in a Murine Tumor Model Using a Monoclonal Antibody Specific for the La Autoantigen Clin. Cancer Res., September 15, 2007; 13(18): 5519s - 5527s. [Abstract] [Full Text] [PDF]

				D. A. Hamstra, A. Rehemtulla, and B. D. Ross Diffusion Magnetic Resonance Imaging: A Biomarker for Treatment Response in Oncology J. Clin. Oncol., September 10, 2007; 25(26): 4104 - 4109. [Abstract] [Full Text] [PDF]

				D. A. Torigian, S. S. Huang, M. Houseni, and A. Alavi Functional Imaging of Cancer with Emphasis on Molecular Techniques CA Cancer J Clin, July 1, 2007; 57(4): 206 - 224. [Abstract] [Full Text] [PDF]

				R. L. Ehman, W. R. Hendee, M. J. Welch, N. R. Dunnick, L. B. Bresolin, R. L. Arenson, S. Baum, H. Hricak, and J. H. Thrall Blueprint for Imaging in Biomedical Research Radiology, July 1, 2007; 244(1): 12 - 27. [Full Text] [PDF]

				D. A. Mankoff, J. F. Eary, J. M. Link, M. Muzi, J. G. Rajendran, A. M. Spence, and K. A. Krohn Tumor-Specific Positron Emission Tomography Imaging in Patients: [18F] Fluorodeoxyglucose and Beyond Clin. Cancer Res., June 15, 2007; 13(12): 3460 - 3469. [Abstract] [Full Text] [PDF]

				W. A. Weber and R. Figlin Monitoring Cancer Treatment with PET/CT: Does It Make a Difference? J. Nucl. Med., January 1, 2007; 48(1_suppl): 36S - 44S. [Abstract] [Full Text] [PDF]